Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ODTC Stock Summary
In the News
ODTC Financial details
Company Rating
Neutral
Market Cap
34.64K
Income
-112.49M
Revenue
0
Book val./share
1.88
Cash/share
2.51
Dividend
-
Dividend %
-
Employees
137
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-0.47
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.43
P/C
0.6
P/FCF
-
Quick Ratio
5.81
Current Ratio
5.91
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-2.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.78%
-
-
-
-
SMA20
-99.55%
SMA50
-99.85%
SMA100
-6.83%
Inst Own
14.26%
Inst Trans
0.22%
ROA
-75%
ROE
-85%
ROC
-0.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
19.25K
Shs Float
17.57K
-
-
-
-
Target Price
-
52W Range
1.5-2.42
52W High
-25%
52W Low
+50%
RSI
48.11
Rel Volume
-
Avg Volume
2.63K
Volume
Perf Week
0%
Perf Month
0%
Perf Quarter
-12.79%
Perf Half Y
-16.67%
-
-
-
-
Beta
0.027662
-
-
Volatility
0%, 747.96%
Prev Close
0%
Price
1.5
Change
0%
ODTC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.11 | -2.31 | -3.64 | -3.94 | -3.84 | |
Operating cash flow per share | -0.06 | -1.82 | -2.74 | -3.5 | -3.44 | |
Free cash flow per share | -0.06 | -1.83 | -2.82 | -3.5 | -3.46 | |
Cash per share | 0.1 | 13.98 | 5.68 | 6.53 | 4.79 | |
Book value per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
Tangible book value per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
Share holders equity per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
Interest debt per share | 0 | 0 | 0 | 0.07 | 0.16 | |
Market cap | 1236.96B | 708.47B | 688.86B | 1792.89B | 1261.92B | |
Enterprise value | 1236.95B | 708.28B | 688.72B | 1792.71B | 1261.77B | |
P/E ratio | -400.96K | -21.64K | -7.74K | -16.49K | -9.99K | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -713.77K | -27.4K | -10.27K | -18.55K | -11.15K | |
PFCF ratio | -713.77K | -27.31K | -9.98K | -18.52K | -11.11K | |
P/B Ratio | 541.81K | 3.61K | 5.56K | 11.05K | 9.27K | |
PTB ratio | 541.81K | 3.61K | 5.56K | 11.05K | 9.27K | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -400.96K | -21.64K | -7.62K | -15.65K | -9.94K | |
EV to operating cash flow | -713.76K | -27.39K | -10.26K | -18.55K | -11.15K | |
EV to free cash flow | -713.76K | -27.3K | -9.98K | -18.52K | -11.11K | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0.01 | 0.04 | |
Debt to assets | 0 | 0 | 0 | 0.01 | 0.03 | |
Net debt to EBITDA | 0.84 | 6.05 | 1.54 | 1.56 | 1.2 | |
Current ratio | 4.79 | 27.02 | 7.68 | 7.42 | 5.91 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.56 | 0.79 | 0.75 | 0.86 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.26 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.03 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -4.15 | -5.45 | -0.44 | -0.97 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.47 | 26.82 | 20.37 | 22.81 | 18.93 | |
ROIC | -1.35 | -0.17 | -0.75 | -0.67 | -0.87 | |
Return on tangible assets | -1.07 | -0.16 | -0.62 | -0.58 | -0.75 | |
Graham Net | 0.07 | 13.45 | 4.92 | 5.57 | 3.82 | |
Working capital | 2.27M | 195.43M | 121.59M | 159.15M | 132.8M | |
Tangible asset value | 2.28M | 195.98M | 124M | 162.3M | 136.15M | |
Net current asset value | 2.27M | 195.43M | 121.13M | 157.4M | 128.13M | |
Invested capital | 0 | 0 | 0 | 0.01 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 300.5K | 2.44M | 7.54M | 13.18M | 14.88M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.35 | -0.17 | -0.72 | -0.67 | -0.93 | |
Capex per share | 0 | -0.01 | -0.08 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.93 | 0 | -0.9 | -0.59 | -0.63 | |
Operating cash flow per share | -0.77 | 0 | -0.67 | -0.61 | -0.4 | |
Free cash flow per share | -0.77 | 0 | -0.67 | -0.61 | -0.4 | |
Cash per share | 5.74 | 0 | 3.56 | 2.9 | 2.51 | |
Book value per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
Tangible book value per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
Share holders equity per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
Interest debt per share | 0.16 | 0 | 0.14 | 0.13 | 0.13 | |
Market cap | 881.59B | 1261922B | 255.82B | 264.7B | 220.71B | |
Enterprise value | 881.41B | 1261921.84B | 255.69B | 264.59B | 220.62B | |
P/E ratio | -7.23K | -9.77M | -1.89K | -2.94K | -2.3K | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -35.05K | -40.06M | -10.27K | -11.49K | -14.62K | |
PFCF ratio | -34.78K | -40.04M | -10.26K | -11.49K | -14.62K | |
P/B Ratio | 5.32K | 9.27M | 2.43K | 3.13K | 3.09K | |
PTB ratio | 5.32K | 9.27M | 2.43K | 3.13K | 3.09K | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -28.92K | -39.06M | -7.6K | -12.6K | 36.85K | |
EV to operating cash flow | -35.04K | -40.06M | -10.26K | -11.49K | -14.61K | |
EV to free cash flow | -34.77K | -40.04M | -10.26K | -11.49K | -14.61K | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | |
Debt to assets | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | |
Net debt to EBITDA | 6 | 4.7 | 3.8 | 5 | -15.06 | |
Current ratio | 6.68 | 5.91 | 4.11 | 3.78 | 3.29 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.83 | 0.98 | 0.74 | 1.05 | 1.08 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.15 | -0.13 | -0.17 | -0.04 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 10.27 | 0.01 | 7.56 | 5.46 | 5.17 | |
ROIC | -0.17 | -0.22 | -0.29 | -0.24 | 0.12 | |
Return on tangible assets | -0.15 | -0.19 | -0.24 | -0.19 | -0.23 | |
Graham Net | 4.72 | 0 | 2.56 | 2.01 | 1.6 | |
Working capital | 162.19M | 132.8M | 103.01M | 82.42M | 69.29M | |
Tangible asset value | 165.6M | 136.15M | 105.3M | 84.63M | 71.37M | |
Net current asset value | 157.34M | 128.13M | 98.53M | 78.12M | 65.18M | |
Invested capital | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 14.55M | 14.1M | 14.71M | 14.19M | 12.39M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | -0.24 | -0.32 | -0.27 | -0.34 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
ODTC Frequently Asked Questions
What is Odonate Therapeutics, Inc. stock symbol ?
Odonate Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol ODTC
What is Odonate Therapeutics, Inc. stock quote today ?
Odonate Therapeutics, Inc. stock price is $1.5 today.
Is Odonate Therapeutics, Inc. stock public?
Yes, Odonate Therapeutics, Inc. is a publicly traded company.